177 related articles for article (PubMed ID: 1516800)
1. [Current tactics in reducing hazards of virus infection transmission during blood transfusion].
Golosova TV
Gematol Transfuziol; 1992 Mar; 37(3):35-7. PubMed ID: 1516800
[No Abstract] [Full Text] [Related]
2. Reducing the residual risk of transfusion-transmitted viruses: mini-pool or single-donation NAT?
Roth WK; Seifried E
Transfusion; 2001 Jun; 41(6):845-7. PubMed ID: 11399831
[No Abstract] [Full Text] [Related]
3. Strategies for reducing the exposure to donor blood.
Murphy M
Clin Med (Lond); 2005; 5(4):337-40. PubMed ID: 16138487
[No Abstract] [Full Text] [Related]
4. [Viral safety measures of plasma for transfusion and applicability in Spain].
Pereira A
Med Clin (Barc); 2007 Oct; 129(12):458-68. PubMed ID: 17953912
[No Abstract] [Full Text] [Related]
5. Kill and cure. The hope and reality of virus inactivation.
Prowse C
Vox Sang; 1994; 67 Suppl 3():191-6. PubMed ID: 7975491
[No Abstract] [Full Text] [Related]
6. Emerging viruses and transfusion.
Allain JP
Transfus Clin Biol; 2001 Jun; 8(3):220-1. PubMed ID: 11499963
[TBL] [Abstract][Full Text] [Related]
7. Is there a limit to the normality of blood products?
Degos L
Hematol J; 2000; 1(5):291. PubMed ID: 11920204
[No Abstract] [Full Text] [Related]
8. Virus inactivation of fresh plasma.
Mohr H
Vox Sang; 1998; 74 Suppl 2():171-2. PubMed ID: 9704442
[No Abstract] [Full Text] [Related]
9. Genomic screening for blood-borne viruses in transfusion settings.
Lee HH; Allain JP
Vox Sang; 1998; 74 Suppl 2():119-23. PubMed ID: 9704433
[No Abstract] [Full Text] [Related]
10. Approaches to the reduction of viral infectivity in cellular blood components and single donor plasma.
Wagner SJ; Friedman LI; Dodd RY
Transfus Med Rev; 1991 Jan; 5(1):18-32. PubMed ID: 1802274
[No Abstract] [Full Text] [Related]
11. Blood program in Japan: current status.
Ikeda H
Transfus Apher Sci; 2002 Apr; 26(2):129-33. PubMed ID: 12121069
[No Abstract] [Full Text] [Related]
12. Virus safety of human blood, plasma, and derived products.
Guertler L
Thromb Res; 2002 Oct; 107 Suppl 1():S39-45. PubMed ID: 12379292
[TBL] [Abstract][Full Text] [Related]
13. Reducing the risk of virus transmission by blood products.
Thomas DP
Br J Haematol; 1988 Dec; 70(4):393-5. PubMed ID: 3064802
[No Abstract] [Full Text] [Related]
14. [Can virus safety of blood products be assured?].
Krusius T
Duodecim; 1994; 110(13):1227-30. PubMed ID: 7497931
[No Abstract] [Full Text] [Related]
15. Science, lawyers, and "the Europeans": testing requirements in transfusion medicine.
Seitz R; Burger R
Transfusion; 1998 May; 38(5):506-7. PubMed ID: 9633565
[No Abstract] [Full Text] [Related]
16. Safety of the blood supply in the United States: opportunities and controversies.
AuBuchon JP; Birkmeyer JD; Busch MP
Ann Intern Med; 1997 Nov; 127(10):904-9. PubMed ID: 9382369
[TBL] [Abstract][Full Text] [Related]
17. Risks of blood transfusion-2002.
Sandler SG
Curr Opin Hematol; 2002 Nov; 9(6):509-10. PubMed ID: 12394173
[No Abstract] [Full Text] [Related]
18. Molecular virology in transfusion medicine laboratory.
Candotti D; Allain JP
Blood Transfus; 2013 Apr; 11(2):203-16. PubMed ID: 23356973
[No Abstract] [Full Text] [Related]
19. The role of leukodepletion in the control of transfusion-transmitted disease.
Goldman M; Delage G
Transfus Med Rev; 1995 Jan; 9(1):9-19. PubMed ID: 7719040
[No Abstract] [Full Text] [Related]
20. ABC of transfusion. Infectious complications of blood transfusion: viruses.
Barbara JA; Contreras M
BMJ; 1990 Feb; 300(6722):450-3. PubMed ID: 2107902
[No Abstract] [Full Text] [Related]
[Next] [New Search]
